AUTHORS
Honghang Zhou, Chengcheng Fu, MD,PhD2, Lingzhi Yan3, Jingjing Shang, PhD4, Shuang Yan5, Xiaolan Shi6, Song Jin7, Yingying Zhai, MD, PhD8, Weiqin Yao9, Depei Wu Sr, MD10
AFFILIATIONS
1 First Affiliated Hospital of Soochow University, Suzhou, China
2 First Affiliated Hospital of Soochow University, Suzhou, China, Jiangsu Institute of Hematology,, Suzhou, China, Jiangsu Key Laboratory of Hematologic Diseases, Suzhou, China, National Clinical Research Center for Hematologic Diseases, Suzhou, China
3 First Affiliated Hospital of Soochow University, Suzhou, China
4 First Affiliated Hospital of Soochow University, Suzhou, China
5 First Affiliated Hospital of Soochow University, Suzhou, China
6 First Affiliated Hospital of Soochow University, Suzhou, China
7 First Affiliated Hospital of Soochow University, Suzhou, China
8 First Affiliated Hospital of Soochow University, Suzhou, China
9 First Affiliated Hospital of Soochow University, Suzhou, China
10 First Affiliated Hospital of Soochow University, Suzhou, China
ABSTRACT
Background
Zevorcabtagene autoleucel (Zevor-cel) is a fully humanized BCMA-targeting CAR-T treatment approved in China in February 2024 for patients with relapsed/refractory multiple myeloma who have received at least three prior lines of therapy. Since Zevor-cel has been on the market in China for a relatively short period, long-term follow-up data are lacking. Therefore, we conducted a retrospective analysis of patients who received CART treatment at a single center, including those from clinical studies and those in the real-world setting after the product was launched on the market.
Methods
This study enrolled 26 R/RMM patients who received Zevor-cel at the First Affiliated Hospital of Soochow University between September 24, 2019, and March 31, 2026. All Patients received lymphodepleting chemotherapy consisting of fludarabine 25 mg/m²)and cyclophosphamide 300 mg/m² for 3 consecutive days, administered 2–5 days prior to CAR-T cell infusion, with doses adjusted according to creatinine clearance. Subsequently, a dose of 1.5×108 CAR-T cells were infused. The primary endpoint was progression-free survival and NGF-MRD negativity (10-5) rate. Secondary endpoints included overall response rate (ORR) and safety.
Results
Among the 26 enrolled patients, the median age was 60 years (34–83 years), with a median of 3 prior lines of therapy (1–6 lines). Before CAR-T cells infusion, 15 patients (58%) presented with biochemical progression, and 9 patients (43%) had high-risk cytogenetic abnormalities. Thirteen patients (50%) were double-class refractory, and 9 patients (34%) were refractory to at least triple classes. Six patients (23%) of patients had extramedullary disease. Circulating tumor cells ≥ 0.2% were detected in 4 patients (31%). Six patients (23%) were stratified as high-risk by the MyCARe score. 8 patients (31%) underwent bridging therapy.
The ORR were 100%: 26.9% VGPR, 23.1% CR, and 50% sCR. As of June 30, 2026, the median follow-up duration was 33.5 months (2-75 months). The median PFS was 35 months, median OS was not reached, and the 3-year OS rate is 78.5%. Significant differences in PFS were observed among patients stratified into high-, intermediate-, and low-risk groups by the MyCARe score: (7m vs. 24m vs. 45.5m, P<0.0001). For safety, all patients had treatment-related adverse events, mainly hematological toxicities. Cytokine release syndrome (CRS) occurred in 88.5% of patients, all of grade 1–2. One patient developed CRS-associated capillary leak syndrome, and no neurotoxicity or ICANS was observed.
Conclusion
Zevor-cel demonstrated superior efficacy and manageable safety in patients with R/RMM. Patients with aggressive relapse, triple-and-penta-drug resistance, and soft tissue extramedullary disease could be with high response, but the duration is relatively short. Maintenance treatment needs to be considered to improve the prognosis of MyCARe high risk patients. Nevertheless, larger sample sizes studies are warranted to validate these findings.
DISCLOSURES
Honghang Zhou: No relevant conflicts of interest to declare.